TABLE 5.
Prevalence of Escherichia coli ST131 among ESBL-producing and fluoroquinolone-resistant E. coli isolatesa
| Isolate type, sample type, and country(ies) | Study period | Study and population characteristics | % of E. coli ST131 among E. coli isolates |
Reference | |
|---|---|---|---|---|---|
| ESBL+ | FQr | ||||
| ESBL+ isolates | |||||
| Any sample | |||||
| Czech Republic | 2006 | Prospective study (one hospital), any sample, 9 ESBL+ E. coli isolates | 44 | 72 | |
| Spain | 2006-2007 | Prospective study (one hospital, Lugo), any sample, outpatients, 105 ESBL+ E. coli isolates | 22 | 138 | |
| Spain | 2008 | Prospective study (one hospital, Barcelona), any sample, 94 ESBL+ E. coli isolates | 32 | 96 | |
| UK | 2006 | West Midlands region (13 hospitals), CA and HA infections, any sample, 232 ESBL+ E. coli isolates | 66 | 139 | |
| Canada | 2007-2009 | National study (hospital), any sample, 155 ESBL+ E. coli isolates | 50 | 140 | |
| Denmark | 2008-2009 | Retrospective study (three hospitals and 100 general practitioners, Copenhagen), 115 ESBL+ E. coli isolates | 38 | 20 | |
| Switzerland | 2011 | Prospective study (one hospital), CA and HA infections, any sample, 30 ESBL+ E. coli isolates | 33 | 75 | |
| US | 2009-2010 | Prospective, multicenter study, CA infections, any sample, 292 ESBL+ E. coli isolates | 54 | 93 | |
| US | 2010-2011 | Prospective study among children (one hospital), any sample, 68 ESBL+ E. coli isolates | 10 | 141 | |
| US (18 states) | 2010-2011 | 24 laboratories serving the Department of Veterans Affairs, any sample, each laboratory provided 10 FQr and 10 FQsb E. coli isolates (2011) and10 ESBL+ E. coli isolates (2010-2011) | 64 | 78 | 45 |
| Japan | 2008-2011 | Retrospective study (one hospital), any sample, 71 ESBL+ E. coli isolates | 52 | 142 | |
| UTI | |||||
| France | 2006 | Prospective national survey from private laboratories, UTI ESBL+ Enterobacteriaceae among which were 48 ESBL+ E. coli isolates | 21 | 86 | |
| Sweden | 2007-2011 | National survey, 851 UTI ESBL+ E. coli isolates | 34 | 143 | |
| India | 2009 | Retrospective study (one hospital, Pune), 100 UTI isolates, 23 ESBL+ | 70 | 73 | |
| South America | 2006-2007 | CA UTI isolates (one center, Mexico), 500 ESBL+ E. coli isolates of which 56 were molecularly studied | 25 (of 56 isolates) | 144 | |
| Bacteremia | |||||
| France | 2005 | Multicenter study, bacteremia, 19 ESBL+ E. coli isolates | 32 | 94 | |
| Canada | 2000-2010 | Retrospective study, bacteremia, 197 ESBL+ E. coli isolates | 60 | 145 | |
| South Korea | 2006-2011 | Retrospective study, CA bacteremia, 103 ESBL+ E. coli isolates of which 76 were molecularly studied | 20 (of 76 isolates) | 146 | |
| Travel | |||||
| Canada | 2004-2006 | Prospective study, travel-related infections, any sample, 105 ESBL+ isolates of which 68 produced CTX-M-15 or CTX-M-14 | 53 (of 68 isolates) | 147 | |
| UK | 2006-2008 | Prospective study, travel-acquired diarrhea, stool samples, 174 CTX-M-15-producing isolates | 11.5 | 78 | |
| Canada | 2009 | Prospective case-control study, diarrheal stool samples, 26 ESBL+ isolates form travelers and 5 ESBL+ isolates from nontravelers | 23 (of 26 isolates), 40 (of 5 isolates) | 148 | |
| FQr isolates | |||||
| Europe (8 countries) | 2003-2006 | Uncomplicated CA UTI, 148 FQr E. coli isolates from womenc | 24 | 51 | |
| Canada | 2002-2004 | Multicenter study, ambulatory patients,d 199 UTI isolates randomly selected among E. coli isolates susceptible and/or resistant to TS and/or FQ | 44 | 50 | |
| Japan, South Korea, China | 1998-2007 | Multicenter study, any sample, 219 FQr E. coli isolates | 34 | 95 | |
| South Korea | 2006-2007 | CA UTI from 7 regions, 154 FQr E. coli isolates | 25 | 149 | |
a
Abbreviations: CA, community acquired; HA, hospital acquired; UTI, urinary tract infection; ESBL, extended-spectrum β-lactamase; TS, trimethoprim-sulfamethoxazole; FQ, fluoroquinolone; ESBL+, ESBL producing; ICU, intensive care unit.
b
Among FQs isolates, 7% were ST131.
c
ARES study.
d
NAUTICA survey.